GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » Quality Rank

Lexaria Bioscience (Lexaria Bioscience) Quality Rank


View and export this data going back to 2021. Start your Free Trial

What is Lexaria Bioscience Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Lexaria Bioscience Quality Rank Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » Quality Rank
Comparable Companies
PHGE MBIO MYMD APM BCLI GNPX SEEL NNVC LABP VBIV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
LEXX:USA
Address
740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7
Website
https://www.lexariabioscience.com
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.